Prof. Shailendra Kumar Verma

La Jolla Institute for Immunology, LJI, California, USA

Email: [email protected]

Qualifications

2009  Ph.D., Dr BR Ambedker University, India

2001  M.S., Dr BR Ambedker University, India

1997  B.S., Dr BR Ambedker University, India

Publications (Selected)

1. Pinto, P. B. A., Timis, J., Chuensirikulchai, K., et al. (2024). Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron. NPJ Vaccines, 9(1), Article 252.
2. Verma, S. K., Ana-Sosa-Batiz, F., Timis, J., et al. (2024). Influence of Th1 versus Th2 immune bias on viral, pathological, and immunological dynamics in SARS-CoV-2 variant-infected human ACE2 knock-in mice. EBioMedicine, 108, Article 105361.
3. Bisen, S., Verma, S. K., Mukhopadhyay, C. S., et al. (2024). A neutrophil elastase-generated mature form of IL-33 is a potent regulator of endothelial cell activation and proliferative retinopathy. Experimental and Molecular Medicine, 56(8), 1703-1716.
4. Gupta, A., Mahajan, P., Bhagyawant, S. S., et al. (2024). Recombinant YopE and LcrV vaccine candidates protect mice against plague and yersiniosis. Heliyon, 10(10), Article e31446.
5. Aggarwal, R., Mahajan, P., Pandiya, S., et al. (2024). Antibiotic resistance: a global crisis, problems and solutions. Critical Reviews in Microbiology, 50(5), 896-921.
6. Narayan, B., Verma, S. K., Singh, S., et al. (2023). Protective antigen of Bacillus anthracis in combination with TLR4 or TLR5 agonist confers superior protection against lethal challenge in mouse model. Microbes and Infection, 25(8), Article 105183.
7. Saxena, D., Batra, L., & Verma, S. K. (2023). Broad-Spectrum Antivirals against Multiple Human and Animal Coronaviruses Infection. Pathogens, 12(6), Article 823.
8. Saxena, D., Batra, L., & Verma, S. K. (2023). Safety, Tolerability, and Immunogenicity of COVID-19 Bivalent Vaccination. Vaccines, 11(6), Article 1040.
9. Ana-Sosa-Batiz, F., Verma, S. K., Shafee, N., et al. (2023). A new mouse model expressing human ACE2, TMPRSS2, and FCGRT for evaluating human antibody responses to SARS-CoV-2. Journal of Immunology, 210(1, Suppl. S).
10. Verma, S. K., Ana-Sosa-Batiz, F., Shafee, N., et al. (2023). SARS-CoV-2 Delta requires human ACE2 but not human TMPRSS2 to infect mice and elicits greater lung injury and adaptive immune response than Omicron in human ACE2 knock-in mice. Journal of Immunology, 210(1, Suppl. S), Article 75.04.
11. Alves, R. P. D., Wang, Y. T., Mikulski, Z., et al. (2023). SARS-CoV-2 Omicron (B.1.1.529) shows minimal neurotropism in a double-humanized mouse model. Antiviral Research, 212, Article 105580.
12. Verma, S. K., Mahajan, P., Singh, N. K., et al. (2023). New-age vaccine adjuvants, their development, and future perspective. Frontiers in Immunology, 14, Article 1043109.
13. Athirathinam, K., Nandakumar, S., Verma, S. K., et al. (2023). Determination of Conformational and Functional Stability of Potential Plague Vaccine Candidate in Formulation. Vaccines, 11(1), Article 27.
14. Kaur, G., Verma, S. K., Singh, D., et al. (2023). Role of G-Proteins and GPCRs in Cardiovascular Pathologies. Bioengineering-Basel, 10(1), Article 76.
15. Regla-Nava, J. A., Wang, Y. T., Fontes-Garfias, C. R., et al. (2022). A Zika virus mutation enhances transmission potential and confers escape from protective dengue virus immunity. Cell Reports, 39(2), Article 110655.
16. Gupta, A., Narayan, B., Kumar, S., & Verma, S. K. (2020). Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis. Frontiers in Immunology, 11, Article 988.
17. Verma, S. K., Gupta, A., Batra, L., et al. (2019). Escherichia coli expressed flagellin C (FliC) of Salmonella Typhi improved the protective efficacy of YopE against plague infection. Vaccine, 37(1), 19-24.
18. Verma, S. K., & Tuteja, U. (2016). Plague Vaccine Development: Current Research and Future Trends. Frontiers in Immunology, 7, Article 602.
19. Verma, S. K., Batra, L., & Tuteja, U. (2016). A Recombinant Trivalent Fusion Protein F1-LcrV-HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis. Frontiers in Microbiology, 7, Article 1053.
20. Batra, L., Verma, S. K., Nagar, D. P., et al. (2014). RETRACTED: HSP70 Domain II of Mycobacterium tuberculosis Modulates Immune Response and Protective Potential of F1 and LcrV Antigens of Yersinia pestis in a Mouse Model. PLOS Neglected Tropical Diseases, 8(12), Article e3322.

profiles Details
https://scholar.google.com/citations?user=WkFnpLUAAAAJ&hl=en
https://www.researchgate.net/profile/Shailendra-Verma-3

WOS ResearcherID: GYU-7804-2022